Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2003

Open Access 01-12-2003 | Original investigation

Monocyte matrix metalloproteinase production in Type 2 diabetes and controls – a cross sectional study

Authors: Mark D Baugh, Jelena Gavrilovic, Isabel R Davies, David A Hughes, Mike J Sampson

Published in: Cardiovascular Diabetology | Issue 1/2003

Login to get access

Abstract

Background

Coronary plaque rupture may result from localised over expression of matrix metalloproteinases (MMPs) within the plaque by infiltrating monocyte – macrophages. As MMP expression can be promoted by the modified lipoproteins, oxidative stress and hyperglycaemia that characterises Type 2 diabetes, we hypothesised that peripheral monocytes in these patients, exposed to these factors in vivo, would demonstrate increased MMP production compared to controls.

Methods

We examined peripheral venous monocyte expression of MMP and tissue inhibitor of metalloproteinase-1 (TIMP-1) in 18 controls and 22 subjects with Type 2 diabetes and no previous cardiovascular complications.

Results

No significant difference in MMP-1, 3 or 9 or TIMP-1 production was observed between control and diabetes groups.

Conclusions

Monocyte MMP-1, 3, and 9, and TIMP-1, production are not abnormal in Type 2 diabetes. This data cannot be extrapolated to monocyte – macrophage behaviour in the vessel wall, but it does suggest MMP and TIMP-1 expression prior to monocyte infiltration and transformation are not abnormal in Type 2 diabetes.
Literature
1.
Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P: Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilisation. Am J Med. 1998, 104: 145-185. 10.1016/S0002-9343(98)00041-2.CrossRef
2.
Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem. 1999, 274: 21491-21494. 10.1074/jbc.274.31.21491.CrossRefPubMed
3.
Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Nat Acad Sci USA. 1996, 93: 9748-9753. 10.1073/pnas.93.18.9748.PubMedCentralCrossRefPubMed
4.
Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metallo proteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994, 94: 2493-2503.PubMedCentralCrossRefPubMed
5.
Wei M, Gaskill SP, Haffner SM, Stern MP: Effects of diabetes and level of glycaemia on all cause and cardiovascular mortality. Diabetes Care. 1998, 21: 1167-1172.CrossRefPubMed
6.
Desfaits AC, Serri O, Renier G: Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in Type 2 diabetes patients after gliclazide treatment. Diabetes Care. 1998, 21: 487-493.CrossRefPubMed
7.
Zhang Y, McCluskey K, Fujii K, Wahl LM: Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol. 1998, 161: 3071-3076.PubMed
8.
Braschi S, Astley SB, Sampson MJ: Baseline diene conjugates in plasma low-density lipoprotein and paraoxonase activity in Type-2 diabetes and controls. Diabetologia. 2001, 44 (Suppl 1): A1232.
9.
Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999, 99: 993-998.CrossRefPubMed
10.
Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001, 88: 1291-1298.CrossRefPubMed
11.
Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA: CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993, 268: 11811-11816.PubMed
12.
DECODE study group: Glucose tolerance and mortality : comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999, 354: 617-621. 10.1016/S0140-6736(98)12131-1.CrossRef
13.
Hughes DA, Townsend PJ, Haslam PL: Enhancement of the antigen-presenting function of monocytes by cholesterol: possible relevance to inflammatory mechanisms in extrinsic allergic alveolitis and atherosclerosis. Clin Exp Immunol. 1992, 87: 279-286.PubMedCentralCrossRefPubMed
14.
Clark IM, Powell LK, Wright JK, Cawston TE, Hazleman BL: Monoclonal antibodies against human fibroblast collagenase and the design of an enzyme-linked immunosorbent assay to measure total collagenase. Matrix. 1992, 12: 475-480.CrossRefPubMed
15.
Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS: Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999, 117: 814-822.CrossRefPubMed
16.
Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001, 88: 1291-1298.CrossRefPubMed
17.
Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A: Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes. 2002, 51: 3063-3068.CrossRefPubMed
18.
Wall SJ, Bevan D, Thomas DW, Harding KG, Edwards DR, Murphy G: Differential expression of matrix metalloproteinases during impaired wound healing of the diabetes mouse. J Invest Dermatol. 2002, 119: 91-98. 10.1046/j.1523-1747.2002.01779.x.CrossRefPubMed
19.
Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H: Expression of matrix metalloproteinases and their inhibitors in the wounds of diabetic and non diabetic patients. Diabetologia. 2002, 45: 1011-1016. 10.1007/s00125-002-0868-8.CrossRefPubMed
20.
Ebihara I, Nakamura T, Shimada N, Koide H: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1998, 32: 544-550.CrossRefPubMed
21.
Maxwell PR, Timms PM, Chandran S, Gordon D: Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabetic Med. 2001, 18: 777-780. 10.1046/j.1464-5491.2001.00542.x.CrossRefPubMed
22.
Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano JS: Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res. 2000, 60: 2555-2561.PubMed
23.
Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998, 18: 1671-1678.CrossRefPubMed
24.
O'Brien RC, Luo M, Balazs N, Mercuri J: In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications. 2000, 14: 201-206. 10.1016/S1056-8727(00)00084-2.CrossRefPubMed
Metadata
Title
Monocyte matrix metalloproteinase production in Type 2 diabetes and controls – a cross sectional study
Authors
Mark D Baugh
Jelena Gavrilovic
Isabel R Davies
David A Hughes
Mike J Sampson
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2003
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-2-3

Other articles of this Issue 1/2003

Cardiovascular Diabetology 1/2003 Go to the issue

Original investigation

Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance.

Original investigation

Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model

Original investigation

High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study

Original investigation

The insertion/deletion variation in the α2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in sib-pairs from families with type 2 diabetes

Original investigation

Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus

Review

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits